Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

CNS Depressants: Alcohol and Nicotine01:27

CNS Depressants: Alcohol and Nicotine

Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex, leading to...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Depressants01:28

Depressants

Depressant drugs, including alcohol and sedative-hypnotics, diminish central nervous system activity by enhancing the action of gamma-aminobutyric acid (GABA), a neurotransmitter that reduces brain activity and promotes relaxation. These substances can have various therapeutic uses but also pose significant risks, especially when misused or combined.
Alcohol is a common depressant that can induce a sense of relaxation and reduced inhibition at low doses. Contrary to its occasional...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sidney George Shaw, DPhil (1948-2017).

Physiological research·2019
Same author

Kindling and withdrawal changes at the benzodiazepine receptor.

Journal of psychopharmacology (Oxford, England)·2011
Same author

The importance of glucocorticoids in alcohol dependence and neurotoxicity.

Alcoholism, clinical and experimental research·2010
Same author

Nimodipine prior to alcohol withdrawal prevents memory deficits during the abstinence phase.

Neuroscience·2008
Same author

Selective increases in regional brain glucocorticoid: a novel effect of chronic alcohol.

Neuroscience·2008
Same author

Social defeat increases alcohol preference of C57BL/10 strain mice; effect prevented by a CCKB antagonist.

Psychopharmacology·2005
Same journal

Effects of Different Exercise Intensities on Internet Addiction in Adolescents and Young Adults: A Systematic Review and Network Meta-Analysis.

Addiction biology·2026
Same journal

Abuse Potential and Neurotoxic Effects of the Synthetic Cannabinoid 4F-ABUTINACA Self-Administration in Adult Male Rats.

Addiction biology·2026
Same journal

Longitudinal Cognitive Evolution in Alcohol Use Disorder Patients: Role of Inflammation, Time of Abstinence and Apolipoprotein Profile.

Addiction biology·2026
Same journal

The Interplay Between Sleep Disturbance, Glymphatic Dysfunction and Altered Brain Networks in Internet Gaming Disorder: A Multimodal Neuroimaging Study.

Addiction biology·2026
Same journal

Correction to "Learning Mechanisms in Alcohol Use Disorders".

Addiction biology·2026
Same journal

Abnormal Brain Structural Covariance Networks of Cortical Thickness in Cocaine Use Disorder.

Addiction biology·2026
See all related articles

Related Experiment Video

Updated: Jun 12, 2026

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder
05:12

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

Published on: June 23, 2023

Concurrent chronic administration of a CCK(B) antagonist can decrease tolerance to the ataxic effects of ethanol.

J Wilson1, G N Woodruff, H J Little

  • 1Parke-Davis Neuroscience Research Unit, Addenbrookes Hospital Site, Cambridge, UK.

Addiction Biology
|June 26, 2010
PubMed
Summary
This summary is machine-generated.

The CCK(B) antagonist CAM1028 partially reduced ethanol tolerance development in rats. Higher doses of CAM1028 also showed a slight protective effect against ethanol withdrawal symptoms.

More Related Videos

Flypub To Study Ethanol Induced Behavioral Disinhibition and Sensitization
08:13

Flypub To Study Ethanol Induced Behavioral Disinhibition and Sensitization

Published on: May 18, 2020

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
07:31

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice

Published on: January 7, 2019

Related Experiment Videos

Last Updated: Jun 12, 2026

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder
05:12

Chronic Intermittent Ethanol Vapor Exposure Paired with Two-Bottle Choice to Model Alcohol Use Disorder

Published on: June 23, 2023

Flypub To Study Ethanol Induced Behavioral Disinhibition and Sensitization
08:13

Flypub To Study Ethanol Induced Behavioral Disinhibition and Sensitization

Published on: May 18, 2020

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice
07:31

Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice

Published on: January 7, 2019

Area of Science:

  • Neuropharmacology
  • Addiction Research

Background:

  • Chronic ethanol consumption leads to tolerance and withdrawal.
  • Cholecystokinin B (CCK(B)) receptors are implicated in substance abuse.
  • CCK(B) antagonists may modulate ethanol's effects.

Purpose of the Study:

  • To investigate the effects of chronic CCK(B) antagonist CAM1028 administration on ethanol tolerance and withdrawal.
  • To determine dose-dependent effects of CAM1028 on ethanol dependence.

Main Methods:

  • Rats received chronic ethanol via liquid diet.
  • CAM1028 was administered at various doses during chronic ethanol exposure.
  • Ethanol tolerance was assessed using a rotorod test for ataxic effects.
  • Withdrawal signs were monitored after ethanol cessation.

Main Results:

  • CAM1028 did not affect ethanol intake or brain ethanol concentrations.
  • Lower doses of CAM1028 (0.03–0.3 mg/kg) attenuated the development of ethanol tolerance.
  • Higher doses of CAM1028 (1–3 mg/kg) did not affect tolerance.
  • A high dose of CAM1028 (10 mg/kg) showed a minor protective effect against ethanol withdrawal.

Conclusions:

  • CAM1028 exhibits dose-dependent effects on ethanol tolerance and withdrawal.
  • CCK(B) antagonism may represent a potential therapeutic strategy for managing ethanol dependence.
  • Further research is needed to elucidate the precise mechanisms involved.